Pitavastatin Calcium
14 NDCs across 5 manufacturers|14 Generic,0 Brand
Pitavastatin Calcium is used to treat hypercholesterolemia, hyperlipoproteinemias and hypertriglyceridemia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Aug 3, 2009, and the first generic was approved Dec 20, 2016. FDA's Orange Book lists 27 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $128 million on Pitavastatin Calcium across 306,000 claims for 87,000 beneficiaries.
Pitavastatin Calcium is available as 14 NDCs from 5 manufacturers (14 generic, 0 brand), with NADAC prices from $0.90 to $1.03 per EA — a 14% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
14
14G / 0B
Manufacturers
5
competing in market
Price Spread
$0.90 – $1.03
per EA
7d Activity
avg -7.2% WoW · of 14 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Upsher-Smith Laboratories LLC manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
HMG-CoA Reductase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
5 manufacturers producing PITAVASTATIN CALCIUM(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
PITAVASTATIN 4 MG TABLET | $1.0291 per EA | -9.43% |
PITAVASTATIN 4 MG TABLET | $1.0291 per EA | -9.43% |
PITAVASTATIN 4 MG TABLET | $1.0291 per EA | -9.43% |
PITAVASTATIN 4 MG TABLET | $1.0291 per EA | -9.43% |
PITAVASTATIN 4 MG TABLET | $1.0291 per EA | -9.43% |
PITAVASTATIN 2 MG TABLET | $0.9543 per EA | -3.27% |
PITAVASTATIN 2 MG TABLET | $0.9543 per EA | -3.27% |
PITAVASTATIN 2 MG TABLET | $0.9543 per EA | -3.27% |
PITAVASTATIN 2 MG TABLET | $0.9543 per EA | -3.27% |
PITAVASTATIN 2 MG TABLET | $0.9543 per EA | -3.27% |
PITAVASTATIN 1 MG TABLET | $0.9044 per EA | -9.35% |
PITAVASTATIN 1 MG TABLET | $0.9044 per EA | -9.35% |
PITAVASTATIN 1 MG TABLET | $0.9044 per EA | -9.35% |
PITAVASTATIN 1 MG TABLET | $0.9044 per EA | -9.35% |
Frequently Asked Questions
What is Pitavastatin Calcium used to treat?
Pitavastatin Calcium is used to treat hypercholesterolemia, hyperlipoproteinemias and hypertriglyceridemia, per the National Library of Medicine's MED-RT classification.
When did Pitavastatin Calcium become available as a generic?
FDA approved the first generic Pitavastatin Calcium (ANDA) on Dec 20, 2016. The Orange Book currently lists 27 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Pitavastatin Calcium?
In 2024, Medicare Part D spent $128 million on Pitavastatin Calcium across 306,000 claims for 87,000 beneficiaries.
How many Pitavastatin Calcium products are on the market?
The Pitavastatin Calcium drug market contains 14 NDCs from 5 manufacturers — 14 generic and 0 brand products.
What is the price range for Pitavastatin Calcium?
NADAC reference prices for Pitavastatin Calcium range from $0.9044 to $1.0291 per EA — a 14% difference between cheapest and most expensive.
Which manufacturers make Pitavastatin Calcium?
5 manufacturers list Pitavastatin Calcium in NADAC. Ranked by number of NDCs, the largest are Upsher-Smith Laboratories LLC (3), Zydus Pharmaceuticals (USA) Inc. (3), Camber Pharmaceuticals Inc. (3), Teva Pharmaceuticals USA Inc. (3), NorthStar Rx LLC (2).
How has the price of Pitavastatin Calcium changed recently?
Over the past 7 days, 0 Pitavastatin Calcium NDCs rose and 14 fell, with a market-wide average change of -7.2%.